Sarepta Therapeutics, Inc.
Clinical trials sponsored by Sarepta Therapeutics, Inc., explained in plain language.
A biopharmaceutical company focused on RNA-targeted therapies for rare diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Higher dose of muscular dystrophy drug shows promise in new trial Results expected Oct 2026 (estimated)
- New hope for muscle disease: experimental drug ARO-DM1 enters human trials Results expected Dec 2026 (estimated)
- Gene therapy breakthrough? new trial targets duchenne muscular dystrophy Results expected May 2027 (estimated)
- New study aims to make duchenne gene therapy safer for kids Results expected Aug 2027 (estimated)